OncoMatch/Clinical Trials/NCT05995028
Universal 4SCAR7U Targeting CD7-positive Malignancies
Is NCT05995028 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Universal CD7-specific CAR gene-engineered T cells for t-cell acute lymphoblastic leukemia.
Treatment: Universal CD7-specific CAR gene-engineered T cells — The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells. The study also aims to learn more about the function of CD7 targeting CAR T cells and their persistence in patients of hematological malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Biomarker criteria
Required: CD7 expression (positive)
Performance status
KARNOFSKY 81–100
Karnofsky performance status (KPS) score is higher than 80
Prior therapy
Cannot have received: gene therapy
Previous treatment with any gene therapy products
Lab requirements
Blood counts
hgb≥80g/l
Kidney function
creatinine ≤ 2.5 × upper limit of normal
Liver function
ast and alt ≤ 3 × upper limit of normal, total bilirubin ≤ 2.0mg/dl
Cardiac function
cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify